Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | MMP1 | P03956 | 6/20 | 0.42 |
| ▸ | MMP13 | P45452 | 3/20 | 0.42 |
| ▸ | MMP2 | P08253 | 7/20 | 0.38 |
| ▸ | MMP3 | P08254 | 4/20 | 0.38 |
| ▸ | BMP1 | P13497 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5488359 | 1.00 | LTA4H (0.47) | LTA4HCTSSCTSKMMP1MMP13 | |
| SCHEMBL8070574 | 0.87 | MMP1 (0.52) | MMP1MMP13MMP2MMP3 | |
| SCHEMBL14492872 | 0.85 | LTA4H (0.46) | LTA4HCTSSCTSKMMP1MMP13 | |
| SCHEMBL1915283 | 0.83 | CTSK (0.43) | LTA4HCTSSCTSKMMP2CYP2D6 | |
| SCHEMBL1915281 | 0.83 | CTSK (0.43) | LTA4HCTSSCTSKMMP2CYP2D6 | |
| SCHEMBL14492870 | 0.82 | MMP1 (0.37) | LTA4HCTSSCTSKMMP1MMP13 | |
| SCHEMBL5488362 | 0.82 | MMP1 (0.49) | CTSSCTSKMMP1MMP13MMP2 | |
| SCHEMBL5488364 | 0.82 | MMP1 (0.49) | CTSSCTSKMMP1MMP13MMP2 | |
| SCHEMBL1914687 | 0.82 | CTSK (0.45) | LTA4HCTSSCTSKKMT2A | |
| SCHEMBL1704461 | 0.82 | CTSK (0.45) | LTA4HCTSSCTSKKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129310-A1 | Antibacterial agents | VERNALIS (OXFORD) LTD. (GB) | 2007-06-07 | — | — | US | disclosed |
| EP-1554261-A1 | ANTIBACTERIAL AGENTS | Vernalis (Oxford) Limited (GB) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004033441-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LTD (GB) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129310-A1 | Antibacterial agents | ARG1, SCO2, SPOUT1 | LTA4H 2742/4885CTSS 2180/4885CTSK 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.